Electronic Acknowledgement Receipt				
EFS ID:	4899396			
Application Number:	10560300			
International Application Number:				
Confirmation Number:	2524			
Title of Invention:	Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5h antagonists			
First Named Inventor/Applicant Name:	Jean-Paul Rene Marie Andre Bosmans			
Customer Number:	45511			
Filer:	Stephanie A. Barbosa/D. McCarty			
Filer Authorized By:	Stephanie A. Barbosa			
Attorney Docket Number:	PRD2061USPCT			
Receipt Date:	04-MAR-2009			
Filing Date:	12-DEC-2005			
Time Stamp:	10:31:50			
Application Type:	U.S. National Stage under 35 USC 371			

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$130
RAM confirmation Number	5718
Deposit Account	233050
Authorized User	

 $The \ Director \ of the \ USPTO \ is \ hereby \ authorized \ to \ charge \ indicated \ fees \ and \ credit \ any \ overpayment \ as \ follows:$

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	JANM-0773-Reply-to-11-10-08.	150625	yes	10	
		PDF	bc1b1aa0bc4b30002e45b5a275b74b0bd3 165c42	,	
	Multi	part Description/PDF files in .	zip description		
	Document Description		Start	End	
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1	
	Claims		2	5	
	Applicant Arguments/Remarks Made in an Amendment		6	10	
Warnings:					
Information:					
2 Extension of Time	JANM-0773-Petition-for-	327958	no	2	
	2 Extension of filling	Extension.PDF	0d1818f2df2995a4843252594838ec5529c7 85d3		
Warnings:					
Information:					
3 Miscellaneous Incoming Letter	JANM-0773-Transmittal-reply- to-11-10-08.PDF	2186449	no	2	
		a432f430b9cdd9b8c15f46ddcdf716ed0a40 2af1			
Warnings:					
Information:					
4 Fee Worksheet (PTO-06)	fee-info.pdf	30383	no	2	
		2b0c70f43ce397779575367da966c65056b 850b3		2	
Warnings:					
Information:					
		Total Files Size (in bytes)	26	95415	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.